Federal Rescheduling and the Start of the Long Collapse of the Cannabis Industry’s Banking and Insolvency Paradox

For nearly three decades, the American cannabis industry has existed in a condition that can only be described as legally schizophrenic. States have licensed, taxed, regulated, insured, zoned, audited, and in some cases rescued cannabis businesses, while the federal government has simultaneously insisted that every dollar generated by those same businesses is derived from criminal activity. Courts have struggled to reconcile this contradiction. Banks have largely refused to touch it. Insolvency systems are fractured under its weight and relief for bankrupt businesses can only come through receiverships, corporate dissolutions or assignments for the benefit of creditors.

In late 2025, the Trump administration reframed this problem in unusually pragmatic terms. Rather than approaching cannabis through the familiar moral or cultural debates that have dominated federal discourse for decades, the administration presented rescheduling as an institutional necessity.

The administration’s argument was not that cannabis should be “legal,” but that its continued classification as a Schedule I substance had rendered federal banking, tax administration and insolvency law incoherent. Rescheduling, as articulated by the administration, was positioned as a corrective and an attempt to restore some alignment between federal law and economic reality without totally abandoning federal regulatory authority.

That framing is critical. It helps explain both what rescheduling would meaningfully change and what it would not.

The Controlled Substances Act and the Architecture of Federal Illegality

The Controlled Substances Act was designed to classify drugs according to medical utility and abuse potential. Marijuana’s placement in Schedule I, the most restrictive category, carried consequences beyond criminal prosecution. Schedule I substances are defined as having no accepted medical use and a high potential for abuse, a designation that triggers absolute federal prohibitions on manufacture, distribution, possession, and facilitation. Unlike cocaine or methamphetamine, which are tightly regulated but schedulable for medical use, marijuana has remained locked in a category that renders all commercial activity unlawful by Federal standards.

That classification is the legal foundation for civil asset forfeiture, conspiracy liability, money laundering exposure, and, most significantly for the modern industry, the exclusion of cannabis businesses from fair taxation and access to the federal financial system. Under federal law, proceeds from marijuana activity are “funds derived from illegal activity,” regardless of state authorization. This single premise explains nearly every downstream legal problem faced by cannabis operators and their counterparties. 

For years, the federal government attempted to soften the edges of this framework through enforcement discretion. Department of Justice memoranda articulated priorities that focused on minors, cartels, diversion, violence, and public safety. Financial regulators such as FinCen, followed suit, issuing guidance that allowed banks to service cannabis-related businesses so long as institutions engaged in extensive due diligence and filed Suspicious Activity Reports acknowledging the underlying illegality. These policies were never law. They were tolerances and explicit acknowledgments that federal actors would sometimes “look the other way.”  Courts, however, were never willing to do the same.

Banking Access and the Limits of Federal Tolerance

The collapse of the cannabis banking experiment was not the result of hostility, but of structure. Financial institutions are creatures of federal law. They require access to the Federal Reserve system, the payments infrastructure, and deposit insurance regimes that depend on statutory compliance, not prosecutorial discretion. The attempt to create cannabis-only financial institutions exposed this fault line. When such institutions sought direct access to the federal payments system, courts were forced to confront the contradiction directly: a federal court cannot order a federal agency to facilitate conduct that Congress has criminalized.

The significance of this impasse cannot be overstated. It revealed that cannabis banking exclusion was not a policy choice that could be reversed by guidance or appropriations riders. It was the logical consequence of Schedule I classification. As long as marijuana remained in that category, meaningful participation in the federal financial system would remain structurally impossible.

The Trump administration’s rescheduling rationale explicitly acknowledged this reality. The administration did not argue that banks should be more courageous or that regulators should be more flexible. Instead, it recognized that the law itself must change if financial normalization was ever to occur.

State Legalization and the Judicial Response

While federal law ossified, state law evolved rapidly. Beginning with California’s Compassionate Use Act in 1996, states constructed comprehensive regulatory regimes governing medical and adult-use cannabis. These systems imposed licensing requirements, operational controls, security mandates, advertising restrictions, and tax obligations more stringent than those applied to many traditional industries. By the mid-2010s, cannabis had become one of the most heavily regulated agricultural and retail products in the country.  This led to other problems such as over taxation, particularly with the Federal taxation requirements that denied all deductions or depreciations for illegal activity except for costs of goods sold. 

Public opinion followed. Support for legalization climbed steadily across ideological lines, with voters in conservative and liberal states alike approving cannabis reform through ballot initiatives and legislation. By the early 2020s, a supermajority of Americans lived in jurisdictions where some form of cannabis use was lawful under state law.

Yet federal courts consistently refused to treat state authorization as legally transformative. Supreme Court precedent made clear that Congress’s Commerce Clause authority permitted federal prohibition even where activity was intrastate and state licensed. Lower courts echoed this logic, emphasizing that state laws could not affirmatively authorize conduct that federal law prohibited without triggering preemption concerns. Congressional appropriations riders limiting enforcement against state-compliant medical programs offered only temporary relief, explicitly tied to funding cycles and subject to renewal.

The result was a peculiar equilibrium: cannabis businesses could operate openly under state law, but they could not meaningfully interact with core federal institutions.

Insolvency, Receivership, and the Federal Law Trap

Nowhere has this contradiction been more destabilizing than in insolvency proceedings. Bankruptcy law is a federal system administered by federal courts and fiduciaries. Trustees, debtors in possession, and receivers are bound not only by state law, but by federal criminal statutes. When cannabis businesses fail, as many inevitably do, they collide with a system that cannot legally administer their assets.

Bankruptcy courts have repeatedly held that they cannot preside over cases that require trustees to possess, sell, or derive income from marijuana. The reasoning is strikingly consistent across jurisdictions. Courts do not dismiss these cases because they disapprove of cannabis. They dismiss them because administering a marijuana estate would require federal officers, such as the U.S. Trustee (a division of the Department of Justice) to commit federal crimes. The risk of asset forfeiture, money laundering liability, and ongoing illegality renders such cases untenable.

Even attempts to distance the estate from direct cannabis handling, through management companies, real estate leasing, or ancillary services, frequently failed. Courts treated material dependence on cannabis revenue as sufficient cause for dismissal, applying good faith and feasibility doctrines with particular aplomb. A handful of decisions carved out some very narrow exceptions, especially where refusing relief would reward independent wrongdoing or where debtors agreed to cease cannabis operations entirely. These cases are notable precisely because they are rare.

State court receiverships have fared better, operating under state authority and often with the tacit acquiescence of federal agencies. Yet even there, the specter of forfeiture and banking exclusion looms large. Receivers managing cannabis assets must navigate licensing regimes, cash management challenges, security concerns, and compliance risks that far exceed those faced in conventional commercial cases.

Agriculture, Perishability, and the Unresolved PACA Question

Cannabis’s status as an agricultural product adds another layer of complexity. Federal law affords special protections to producers of perishable agricultural commodities through trust mechanisms designed to ensure payment. Cannabis strains, particularly in flower form, resemble traditional herbs and specialty crops in many respects. Yet participation in these federal regimes requires licensure and compliance that Schedule I classification effectively forecloses.

Rescheduling would not automatically resolve these questions, but it would remove a critical legal barrier. By reclassifying cannabis as a substance with accepted medical use, the federal government would open the door to treating cannabis as an agricultural commodity rather than contraband. That shift could have profound implications for lender protections, supplier rights, and receivership administration.

What Rescheduling Does and Does Not Accomplish

The Trump administration’s rescheduling proposal is best understood as a recalibration, not a revolution. Moving cannabis to Schedule III would not legalize recreational use nationwide, eliminate federal oversight, or permit unfettered interstate commerce. It would, however, dismantle the central legal fiction that has governed the industry for decades: that a product regulated, taxed, and relied upon by state governments has “no accepted medical use” and exists entirely outside lawful commerce.

Rescheduling would materially alter banking risk. Financial transactions involving cannabis would no longer be automatically criminal, reshaping anti-money laundering analysis and significantly narrowing SAR obligations. Access to payment systems, credit facilities, and insured depositories would become legally defensible rather than merely tolerated.

Tax law would shift just as dramatically. The elimination of Section 280E penalties would align cannabis taxation with basic principles of net-income assessment, reducing incentives for cash hoarding and informal finance. Insolvency law would follow. Trustees and receivers could more easily administer cannabis estates without risking personal criminal exposure, making restructurings, orderly liquidations, and creditor recoveries feasible for the first time.

What rescheduling would not do is remove cannabis from federal control. Regulatory oversight would likely increase, not decrease, as agencies assert jurisdiction over manufacturing standards, labeling, distribution, and medical claims. The Trump administration is explicit on this point: normalization is not deregulation.

Conclusion

For decades, cannabis law has been defined by contradiction. The Trump administration’s rescheduling initiative represents the first serious attempt to resolve that contradiction at the structural level rather than through informal tolerances and prosecutorial discretion.

For lawyers advising banks, fiduciaries, receivers, and distressed companies, the implications are profound. The question is no longer whether cannabis businesses can exist, they already do, but whether the legal system governing finance and insolvency can continue to pretend that they do not.

Rescheduling will not end cannabis law’s complexity. It will, however, begin to restore coherence to a system that has long operated on many legal fictions. For practitioners, that shift marks the beginning of a new and, hopefully, more manageable era. That being said, it will take years for the system to adapt to rescheduling and there will not be an overnight transformation. 

Richard P. Ormond is a Partner at Buchalter, LLP and is the founder of Stone Blossom Capital, LLC, a receiver and fiduciary services company. 

This communication is not intended to create or constitute, nor does it create or constitute, an attorney-client or any other legal relationship. No statement in this communication constitutes legal advice nor should any communication herein be construed, relied upon, or interpreted as legal advice. This communication is for general information purposes only regarding recent legal developments of interest, and is not a substitute for legal counsel on any subject matter. No reader should act or refrain from acting on the basis of any information included herein without seeking appropriate legal advice on the particular facts and circumstances affecting that reader. For more information, visit www.buchalter.com.